|
|
|
|
||
Re: Pembrolizumab/Ipilimumab combo dataSixty-seven patients (44%) had discontinued all treatment by the time of data cutoff. The 2 main reasons included adverse events (AEs) (n = 31) and disease progression (n = 29). Three patients discontinued treatment because they achieved a complete response (CR).Seems beatable. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
31833 | Re: Pembrolizumab/Ipilimumab combo data | agrossfarm | 2 | 6/16/2016 9:22:25 PM |